Early breast cancer refers to cancer that is confined to the breast or has spread only to nearby lymph nodes, without reaching distant organs. It includes stage 0, stage I, and stage II disease, and it accounts for roughly 92% of breast cancer diagnoses in the United States. The outlook is favorable: when the cancer is still localized to the breast, the five-year relative survival rate is effectively 100%.
How Early Breast Cancer Is Classified
Doctors classify breast cancer by three factors: the size of the tumor (T), whether it has reached lymph nodes (N), and whether it has spread to distant parts of the body (M). Early breast cancer means the M category is 0, meaning no distant spread has been detected.
Within that framework, early breast cancer breaks down into three stages:
- Stage 0 (DCIS): Abnormal cells are found inside a milk duct but have not broken through the duct wall into surrounding breast tissue. This is sometimes called noninvasive or preinvasive breast cancer. The cells don’t yet have the ability to invade nearby tissue, so many experts consider it a precancer rather than a true invasive cancer.
- Stage I: The tumor has become invasive but measures 20 millimeters (about ¾ of an inch) or smaller. Cancer either has not reached any lymph nodes or is present only as tiny clusters no larger than 2 millimeters in one to three underarm lymph nodes.
- Stage II: The tumor is larger than 20 millimeters but not more than 50 millimeters, or cancer has spread to a small number of nearby lymph nodes regardless of tumor size. The cancer still has not traveled to distant organs.
The distinction between these stages matters because it directly shapes treatment decisions, from whether you need surgery alone to whether chemotherapy or hormone-blocking therapy is recommended afterward.
Symptoms You Might Notice
Early breast cancer often produces no symptoms at all, which is why screening mammography catches many cases before a person feels anything unusual. When symptoms do appear, the most common is a new lump in the breast or underarm area. Other changes to watch for include thickening or swelling of part of the breast, dimpling or irritation of the skin, redness or flaky skin on the nipple or breast, a nipple that pulls inward, nipple discharge (especially blood), unexplained pain, or a noticeable change in the breast’s size or shape.
None of these signs automatically means cancer. Many lumps turn out to be cysts or other benign conditions. But any new or persistent change is worth getting checked, because when breast cancer is caught while still localized, treatment is far more effective.
How It’s Detected
Screening mammography remains the primary tool for finding early breast cancer before it causes symptoms. On imaging, tumors at this stage tend to measure around 14 millimeters on average. Physical examination can detect tumors too, with an average detected size of about 12 millimeters in clinical studies, though many early tumors are too small to feel. Ultrasound is often used alongside mammography to get a clearer picture, especially in women with dense breast tissue.
If imaging reveals something suspicious, the next step is a biopsy, where a small sample of tissue is removed and examined under a microscope. The biopsy confirms whether cancer cells are present and identifies two critical features: whether the tumor has hormone receptors (estrogen or progesterone) and whether it overproduces a protein called HER2. These biological markers determine which treatments will work best.
Surgical Options
Surgery is the cornerstone of treatment for early breast cancer, and most people face a choice between two approaches.
Breast-conserving surgery (commonly called a lumpectomy) removes the tumor along with a margin of surrounding tissue while preserving the rest of the breast. It requires radiation therapy afterward to reduce the chance of the cancer returning in the same breast. Studies show that women who have a lumpectomy followed by radiation live just as long as women who have a mastectomy. The tradeoff is a slightly higher chance of the cancer recurring in the treated breast, since more breast tissue remains.
Mastectomy removes the entire breast. It’s a more involved operation with a longer recovery, but radiation is usually not needed afterward. Some people choose mastectomy for peace of mind, because they have a genetic risk factor, or because the tumor’s location makes breast-conserving surgery impractical. Breast reconstruction is an option but adds additional surgeries and recovery time.
If the first lumpectomy doesn’t remove all the cancer with clear margins, a second surgery called a re-excision is needed. This is not uncommon and doesn’t change the long-term outlook.
Checking the Lymph Nodes
During surgery, doctors typically perform a sentinel lymph node biopsy to check whether cancer has reached the underarm lymph nodes. This involves removing just the first one to three nodes that drain from the tumor area. Large clinical trials have shown that for women with no clinical signs of lymph node involvement (no palpable lump or swelling in the armpit), this limited biopsy is sufficient for staging the cancer and preventing regional recurrence, as long as the patient also receives appropriate follow-up treatment and radiation.
Even when one or two sentinel nodes contain cancer, removing additional lymph nodes is often unnecessary if the tumor is 5 centimeters or smaller and the patient is receiving radiation and systemic therapy. This approach spares many women from more extensive surgery and its side effects, which can include chronic arm swelling.
Treatments After Surgery
Depending on the cancer’s biology and stage, you may need additional treatment after surgery to reduce the risk of recurrence.
Hormone Therapy
About two-thirds of breast cancers have hormone receptors, meaning they grow in response to estrogen or progesterone. For these cancers, hormone-blocking medication taken for five years or more can greatly reduce the risk of the cancer coming back, developing a new breast cancer, or dying from the disease. A common approach involves taking one type of hormone blocker for two to three years, then switching to another for another two to three years. Cancers that lack hormone receptors do not respond to these drugs.
Genomic Testing and Chemotherapy Decisions
For hormone receptor-positive early breast cancer, genomic profiling of the tumor can help predict how likely the cancer is to return and whether chemotherapy would meaningfully reduce that risk. These tests analyze the activity of specific genes within the tumor and produce a risk score. For many women with early-stage, hormone-positive disease, genomic testing shows that hormone therapy alone provides sufficient protection, sparing them from chemotherapy and its side effects. For higher-risk scores, adding chemotherapy improves outcomes enough to justify the treatment.
Cancers that are HER2-positive or triple-negative (lacking both hormone receptors and HER2) are more likely to require chemotherapy or targeted therapy even at early stages, because these subtypes tend to be more aggressive.
Survival and Long-Term Outlook
The prognosis for early breast cancer is strong. According to national cancer registry data covering 2015 through 2021, the five-year relative survival rate for localized breast cancer (confined to the breast) is 100%. For regional disease, where cancer has reached nearby lymph nodes, it drops to about 87%. These numbers reflect all subtypes combined; some biological subtypes carry a better prognosis than others.
About 64% of breast cancers are diagnosed at the localized stage and another 28% at the regional stage, meaning the vast majority of people are diagnosed while the disease is still highly treatable. This is one of the strongest arguments for regular screening: catching the cancer before it leaves the breast dramatically changes the outcome.